Biosimilar Development solution center

1. Welcoming The “Era Of ADCs” 12/5/2023

   In an episode of The Business of Biotech podcast, Dr. Loretta Itri sat down to explore antibody-drug conjugates as transformative treatments for a range of intractable diseases.

2. Trends In Next-Generation Delivery Technologies 11/22/2023

   Learn how lipid nanoparticles are enabling a new generation of engineered cell therapies with a push toward more complex cell engineering and gene editing for allogeneic therapies.

3. Genome Editing Using mRNA-Lipid Nanoparticles For CAR T Cell Therapy 11/22/2023

   Gene delivery platforms must support a diversity of genetic engineering strategies for genomic medicine development. Learn how lipid nanoparticles can accelerate development from discovery to scale-up.

4. Legal And IP Protection For New Biotechs 10/31/2023

   Want to ensure you've got your biotech legal, IP, and patent bases covered? Join Business of Biotech host Matt Pillar and BlueSphere Bio CEO and biotech legal expert Keir LoIacono on 11/13 for the live, interactive, and FREE digital event Legal And IP Protection For New Biotechs. 

5. How To Develop A Scalable AAV Process, From Start To Finish 10/24/2023

   We present highlights from a process that has been developed – and continues to be refined – by Cytiva scientists. These insights are framed around common challenges in AAV development and production.

6. Improving The Characterization Of Gene Therapy Products 10/19/2023

   The analysis of over 10 variant callers and other bioinformatics tools for viral variant detection are discussed to better understand how the outcomes can improve gene therapy product characterization.

7. Preformulation Of Excipients In Biologics Development 9/28/2023

   Most of the instability problems of a drug product come from excipients, in particular, they come from impurities in excipients. Those issues are best cleaned up in the preformulation period to determine excipient compatability.

8. COGs Process Economics For Autologous Cell Therapy 8/11/2023

   Analyze the cost distribution over time for autologous CAR T therapy manufacturing using process economics and insights from scientists and R&D. Discover how cell therapy manufacturers can combat these costs.

9. What The ICH Q5A Virus Safety Guidelines Mean For Your Cell & Gene Therapy Product 8/11/2023

   Explore Cell & Gene therapy (CGT) products now within scope of the ICH Q5A guidance, technologies that can replace traditional testing strategies, viral clearance studies expected for vector products, and more.

10. Oligonucleotide Manufacturing: How To Get A Strong Start 7/26/2023

    If you’re developing an antisense oligonucleotide, siRNA, or other oligonucleotide therapeutic, you’re aware of their potential. Explore 5 keys to success for oligo synthesis, scale-up, and manufacturing.